FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2685961074> ?p ?o ?g. }

• W2685961074 endingPage "2566" @default.
• W2685961074 startingPage "2566" @default.
• W2685961074 abstract "2566 Background: Durvalumab is a human monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and CD80. The objectives of this analysis were to develop a population pharmacokinetics (PK) model of durvalumab, to quantitate the effect of patient/disease characteristics on PK, and to compare weight (WT)-based versus fixed dosing regimens. Methods: Data were pooled from two studies: Study 1108 (Phase 1/2; various tumor types) and ATLANTIC (Phase 2; NSCLC). A total of 1324 patients provided data following 0.1 to 20 mg/kg IV durvalumab. The population PK was performed using a non-linear mixed effects modeling approach in NONMEM software. The impact of demographics, clinical indices, and biomarkers on PK was explored. Results: Durvalumab PK was best described using a 2-compartment model with both linear and non-linear clearances. The mean (between-patient variability) linear clearance (CL) and central volume of distribution (V 1 ) were 226 mL/day (~29%) and 3.51 L (~21%), respectively. Although population PK analysis identified a few statistically significant covariates (WT, sex, CrCL, post-baseline ADA, ECOG performance status, LDH, sPDL1 levels, tumor type, and albumin), none were found to be clinically relevant (effect on PK parameters < 30%), indicating no need for dose adjustment. Simulations indicated similar overall PK exposures following WT-based (10 mg/kg Q2W) and fixed dosing regimens (1500 mg Q4W or 750 mg Q2W); with all regimens expected to maintain target trough exposure of ~50 µg/mL in ≥95% patients. In a post-hoc analysis, durvalumab clearance was found to decrease slightly over time, with a mean maximal reduction from baseline value of 15.5%. The decrease in CL was associated with tumor shrinkage, decreased LDH, increased albumin and decreased neutrophil to lymphocyte ratio. The small decrease in CL was not considered relevant to PK exposure or dosing. Conclusions: A population PK model of durvalumab was developed and validated. No dose adjustments were needed based on any patient or disease characteristics. The analysis demonstrated the feasibility of switching to a fixed dose regimen. Clinical trial information: NCT02087423 and NCT01693562." @default.
• W2685961074 created "2017-06-30" @default.
• W2685961074 creator A5022268727 @default.
• W2685961074 creator A5022984824 @default.
• W2685961074 creator A5025497378 @default.
• W2685961074 creator A5029143856 @default.
• W2685961074 creator A5043124797 @default.
• W2685961074 creator A5051762151 @default.
• W2685961074 creator A5061296049 @default.
• W2685961074 creator A5061506787 @default.
• W2685961074 creator A5062972256 @default.
• W2685961074 creator A5069189562 @default.
• W2685961074 creator A5069627913 @default.
• W2685961074 date "2017-05-20" @default.
• W2685961074 modified "2023-09-27" @default.
• W2685961074 title "Population pharmacokinetics of durvalumab and fixed dosing regimens in patients with advanced solid tumors." @default.
• W2685961074 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.2566" @default.
• W2685961074 hasPublicationYear "2017" @default.
• W2685961074 type Work @default.
• W2685961074 sameAs 2685961074 @default.
• W2685961074 citedByCount "6" @default.
• W2685961074 countsByYear W26859610742018 @default.
• W2685961074 countsByYear W26859610742019 @default.
• W2685961074 countsByYear W26859610742020 @default.
• W2685961074 countsByYear W26859610742023 @default.
• W2685961074 crossrefType "journal-article" @default.
• W2685961074 hasAuthorship W2685961074A5022268727 @default.
• W2685961074 hasAuthorship W2685961074A5022984824 @default.
• W2685961074 hasAuthorship W2685961074A5025497378 @default.
• W2685961074 hasAuthorship W2685961074A5029143856 @default.
• W2685961074 hasAuthorship W2685961074A5043124797 @default.
• W2685961074 hasAuthorship W2685961074A5051762151 @default.
• W2685961074 hasAuthorship W2685961074A5061296049 @default.
• W2685961074 hasAuthorship W2685961074A5061506787 @default.
• W2685961074 hasAuthorship W2685961074A5062972256 @default.
• W2685961074 hasAuthorship W2685961074A5069189562 @default.
• W2685961074 hasAuthorship W2685961074A5069627913 @default.
• W2685961074 hasConcept C112705442 @default.
• W2685961074 hasConcept C121608353 @default.
• W2685961074 hasConcept C126322002 @default.
• W2685961074 hasConcept C126894567 @default.
• W2685961074 hasConcept C139254425 @default.
• W2685961074 hasConcept C143998085 @default.
• W2685961074 hasConcept C2776239304 @default.
• W2685961074 hasConcept C2777288759 @default.
• W2685961074 hasConcept C2777701055 @default.
• W2685961074 hasConcept C2777742743 @default.
• W2685961074 hasConcept C2780030458 @default.
• W2685961074 hasConcept C2908647359 @default.
• W2685961074 hasConcept C3020755252 @default.
• W2685961074 hasConcept C67761136 @default.
• W2685961074 hasConcept C71924100 @default.
• W2685961074 hasConcept C98274493 @default.
• W2685961074 hasConcept C99454951 @default.
• W2685961074 hasConceptScore W2685961074C112705442 @default.
• W2685961074 hasConceptScore W2685961074C121608353 @default.
• W2685961074 hasConceptScore W2685961074C126322002 @default.
• W2685961074 hasConceptScore W2685961074C126894567 @default.
• W2685961074 hasConceptScore W2685961074C139254425 @default.
• W2685961074 hasConceptScore W2685961074C143998085 @default.
• W2685961074 hasConceptScore W2685961074C2776239304 @default.
• W2685961074 hasConceptScore W2685961074C2777288759 @default.
• W2685961074 hasConceptScore W2685961074C2777701055 @default.
• W2685961074 hasConceptScore W2685961074C2777742743 @default.
• W2685961074 hasConceptScore W2685961074C2780030458 @default.
• W2685961074 hasConceptScore W2685961074C2908647359 @default.
• W2685961074 hasConceptScore W2685961074C3020755252 @default.
• W2685961074 hasConceptScore W2685961074C67761136 @default.
• W2685961074 hasConceptScore W2685961074C71924100 @default.
• W2685961074 hasConceptScore W2685961074C98274493 @default.
• W2685961074 hasConceptScore W2685961074C99454951 @default.
• W2685961074 hasIssue "15_suppl" @default.
• W2685961074 hasLocation W26859610741 @default.
• W2685961074 hasOpenAccess W2685961074 @default.
• W2685961074 hasPrimaryLocation W26859610741 @default.
• W2685961074 hasRelatedWork W10390674 @default.
• W2685961074 hasRelatedWork W2005101515 @default.
• W2685961074 hasRelatedWork W2021574530 @default.
• W2685961074 hasRelatedWork W2040885378 @default.
• W2685961074 hasRelatedWork W2087821742 @default.
• W2685961074 hasRelatedWork W2123003250 @default.
• W2685961074 hasRelatedWork W2140111850 @default.
• W2685961074 hasRelatedWork W2328213254 @default.
• W2685961074 hasRelatedWork W2397635577 @default.
• W2685961074 hasRelatedWork W4285256702 @default.
• W2685961074 hasVolume "35" @default.
• W2685961074 isParatext "false" @default.
• W2685961074 isRetracted "false" @default.
• W2685961074 magId "2685961074" @default.
• W2685961074 workType "article" @default.